• Subscribe
  • Log In
  • Home
  • Daily Diary
  • Asset Class
    • U.S. Equity
    • Fixed Income
    • Global Equity
    • Commodities
    • Currencies
  • Sector
    • Basic Materials
    • Consumer Discretionary
    • Consumer Staples
    • Energy
    • Financial Services
    • Healthcare
    • Industrials
    • Real Estate
    • Technology
    • Telecom Services
    • Transportation
    • Utilities
  • Latest
    • Articles
    • Video
    • Columnist Conversations
    • Best Ideas
    • Stock of the Day
  • Street Notes
  • Authors
    • Bruce Kamich
    • Doug Kass
    • Jim "Rev Shark" DePorre
    • Helene Meisler
    • Jonathan Heller
    • - See All -
  • Options
  • RMPIA
  • Switch Product
    • Action Alerts PLUS
    • Quant Ratings
    • Real Money
    • Real Money Pro
    • Retirement
    • Stocks Under $10
    • TheStreet
    • Top Stocks
    • Trifecta Stocks
  1. Home
  2. / Jim Cramer

Jim Cramer: Even Safe-Haven Big-Cap Drug Stocks Are Now Broken

Once the safest stocks in the book, the big-cap drug companies are now toxic.
By JIM CRAMER Nov 01, 2018 | 07:13 AM EDT
Stocks quotes in this article: AGN, PFE, AMGN, ABBV, GILD, BMY, MRK, LLY, BAX

It's not just that stocks go down. It's that stocks go down and down and down and down in this market.

Big-cap stocks.

Big-cap stocks that you thought might have had some stability that clearly didn't. Like drug stocks, long the bastion of reliability and dependability.

Not anymore.

Take Allergan (AGN) . Club members of Action Alerts Plus know that I have been tortured by this stock for years, ever since the company got a bid from Pfizer (PFE) and I decided to play arbitrageur instead of ringing the register. The deal fell through and I then rode it down almost in half before booting it -- because I didn't like that it was losing exclusivity on drugs faster than it could get new ones improved.

I then, ignominiously, had to watch it rally furiously after the AAP Charitable Trust took the loss. This week, it gave you a beat and raise that, on the surface, looked like the ultimate comeuppance to the Trust's sale.

However, even as almost every sell sider applauded the quarter, there was enough talk about how CEO Brent Saunders wasn't bringing out enough value quickly enough, that they crushed the stock. You lost about 25 points in a straight line, in a blink of time, if you bought the "good" news of the quarter and the positive instant analysis flash reports that came out immediately.

Allergan has two drugs that have huge possibilities -- an acute migraine drug and one for depression -- but they aren't going to be enough to help 2019. Meanwhile Amgen (AMGN) has a new anti-migraine drug that seems much more effective than the very expensive --but hopefully covered, if you take it -- current standard of care: botox. Amgen's Aimovig is much better than botox, which is a chief reason why we have loaded up on Amgen for the Trust. It is way too low versus where it was a couple of weeks ago.

The result of all of this negativity about a beat and raise? Allergan's stock just won't stop going down.

But Allergan is not alone. For five months, we have been hearing about upcoming drugs that could rival AbbVie's (ABBV) biggest pharmaceutical, Humira, which is expected to bring in $21 billion in sales by 2020.

The drug seems protected against biosimilars in this country. But Europe may be a different story -- and investors understand that the biosimilar threat is a clear and present danger to AbbVie's profits. I thought everyone knew this, knew it when the stock was at $100, but now it is at $77 and uninformed shareholders seem to learn about the threat to the franchise every day. There still seems to be no bottom -- even here. In this godforsaken tape, I don't know what causes one.

Gilead's (GILD) the same. What an incredible Hep C franchise it has. But there's a perception that this drug, after making a fortune for the company's shareholders, is now past its prime, with nothing in the tank, a precept reinforced by the fact that Gilead is introducing its own generic version of its drug 10 years before it loses expiration.

That's a strategy that can only be described as quizzical at best.

Gilead's stock has been a falling knife for ages, not unlike its one-time rival for supremacy, Celgene, as it struggles to make up for lost revenue. Again, like Allergan and Gilead, I do not know what turns it around. They are all toxic.

Needless to say, these aren't alone. Bristol-Myers Squibb (BMY) has been left in the dust byMerck & Co. (MRK) , it's oncological rival. There seems to be no stopping Merck on the upside, like when Eli Lilly (LLY) became Peyton Lilly and took off -- and no there is no stopping Bristol Myers on the downside.

Then yesterday out of nowhere, Baxter International (BAX) has been hit with market share losses and a glut of its own pump product, and I wouldn't get in front of this one even after it just lost 10% of its value in a single session. It seems like the beginning of the swoon.

These used to be safety-first situations. No longer. I would rather have a safety pin jabbed into my hand than to try to hold on to any broken drug stock through these kinds of downturns. It's not just rough for tech, not just rough for FANG, not just rough for housing. It's rough for the once-safest stocks in the book, which are now as toxic and broken as I have ever seen.

Get an email alert each time I write an article for Real Money. Click the "+Follow" next to my byline to this article.

Action Alerts PLUS, which Cramer co-manages as a charitable trust, was long AMGN.

TAGS: Drug Approvals | Fundamental Analysis | Investing | Healthcare | Pharmaceuticals | Jim Cramer

More from Jim Cramer

Jim Cramer: I'll Put My Money With 'Boring but Lucrative' Any Day

Jim Cramer
Sep 29, 2021 1:28 PM EDT

Let's look at that recent downgrade of 'dull' Morgan Stanley and see why exciting is best left for the stadiums and amusement parks -- and not stocks.

Jim Cramer: America's Toughest Job? Finding Workers

Jim Cramer
Sep 28, 2021 12:17 PM EDT

It's the question of our time: Where are the people willing to take on these better paying gigs? Let's see what's going on and what we need to happen.

Jim Cramer: Here's How Analysts Can Be Off By a Wide Margin

Jim Cramer
Sep 24, 2021 12:02 PM EDT

Let's look at the reactions to Nike, Costco and Salesforce to see what happens when they're viewed from a real world perspective.

Jim Cramer: It's Pure Insanity That We Don't Make Chips Here in the U.S.

Jim Cramer
Sep 23, 2021 11:05 AM EDT

While the big guns meet at the White House about the global chip shortage, the president and these companies are approaching this all wrong.

Jim Cramer: Go Ahead, Have a Cow, but I Say Powell and Xi Are Bulls

Jim Cramer
Sep 22, 2021 3:51 PM EDT

We rallied, because China's President Xi and Fed Chair Powell made decisions that they knew would lead to rallies.

Real Money's message boards are strictly for the open exchange of investment ideas among registered users. Any discussions or subjects off that topic or that do not promote this goal will be removed at the discretion of the site's moderators. Abusive, insensitive or threatening comments will not be tolerated and will be deleted. Thank you for your cooperation. If you have questions, please contact us here.

Email

CANCEL
SUBMIT

Email sent

Thank you, your email to has been sent successfully.

DONE

Oops!

We're sorry. There was a problem trying to send your email to .
Please contact customer support to let us know.

DONE

Please Join or Log In to Email Our Authors.

Email Real Money's Wall Street Pros for further analysis and insight

Already a Subscriber? Login

Columnist Conversation

  • 09:41 AM EDT STEPHEN GUILFOYLE

    Reweighting Portfolio Positions Through 5 Trades

    Check out what we're doing in the TheStreet's Stoc...
  • 12:01 PM EDT PAUL PRICE

    A Recent Director Buy in Children's Place (PLCE)

    Four of the most recent insider trades in Children...
  • 07:34 AM EDT PAUL PRICE

    A $525,000 Vote of Confidence on Macerich (MAC)

  • See More

COLUMNIST TWEETS

  • A Twitter List by realmoney
About Privacy Terms of Use

© 1996-2022 TheStreet, Inc., 225 Liberty Street, 27th Floor, New York, NY 10281

Need Help? Contact Customer Service

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data & Company fundamental data provided by FactSet. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by FactSet Digital Solutions Group.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

FactSet calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.

Compare Brokers

Please Join or Log In to manage and receive alerts.

Follow Real Money's Wall Street Pros to receive real-time investing alerts

Already a Subscriber? Login